Pill to make DVT treatment easier

A new anti-coagulant pill will simplify the treatment of deep vein thrombosis (DVT), bringing greater convenience and reduced costs for patients and hospitals.

The Bayer-developed Xarelto, or Rivaroxaban, which has been approved by the Health Sciences Authority here, is the first oral, single-drug approach for the treatment and prevention of DVT.

The condition occurs when a blood clot forms in veins deep inside the muscles of the legs.

If the clot travels to the lungs, it can block blood supply, in a potentially fatal problem known as a pulmonary embolism. — The Straits Times / Asia News Network

Source: The Star

Category: Pharmaceuticals